Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03712137 · ClinicalTrials.gov registry record · Phase 3
Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for Restoring Jawline Definition
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 206
- Enrollment target
NCT03712137 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 206 participants.
The verdict
NCT03712137, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 206 participants
- Enrollment target
Study Summary
This study will evaluate the safety and effectiveness of JUVÉDERM VOLUX™ XC injectable gel for restoring jawline definition
Interventions
- OTHER No-treatment control
- DEVICE VOLUX XC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2018-11-12 |
| Est. Completion | 2021-01-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03712137
The ClinicalTrials.gov registry entry for NCT03712137 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which No-treatment control is the first listed.
NCT03712137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03712137 about?
NCT03712137 is a clinical study titled "Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for Restoring Jawline Definition". This study will evaluate the safety and effectiveness of JUVÉDERM VOLUX™ XC injectable gel for restoring jawline definition
What is the current status of trial NCT03712137?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 206 participants. The study started on 2018-11-12. Estimated completion is 2021-01-26.
What interventions are being tested in trial NCT03712137?
The interventions under investigation include: No-treatment control (OTHER), VOLUX XC (DEVICE).
Who is sponsoring clinical trial NCT03712137?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.